ATE413885T1 - Getrocknete blutfaktorzusammensetzung mit trehalose - Google Patents

Getrocknete blutfaktorzusammensetzung mit trehalose

Info

Publication number
ATE413885T1
ATE413885T1 AT03002147T AT03002147T ATE413885T1 AT E413885 T1 ATE413885 T1 AT E413885T1 AT 03002147 T AT03002147 T AT 03002147T AT 03002147 T AT03002147 T AT 03002147T AT E413885 T1 ATE413885 T1 AT E413885T1
Authority
AT
Austria
Prior art keywords
trehalose
blood factor
factor composition
dried blood
stable
Prior art date
Application number
AT03002147T
Other languages
English (en)
Inventor
Bruce Joseph Roser
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ATE413885T1 publication Critical patent/ATE413885T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03002147T 1995-01-19 1996-01-19 Getrocknete blutfaktorzusammensetzung mit trehalose ATE413885T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501040.1A GB9501040D0 (en) 1995-01-19 1995-01-19 Dried composition

Publications (1)

Publication Number Publication Date
ATE413885T1 true ATE413885T1 (de) 2008-11-15

Family

ID=10768253

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03002147T ATE413885T1 (de) 1995-01-19 1996-01-19 Getrocknete blutfaktorzusammensetzung mit trehalose
AT96900633T ATE245442T1 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96900633T ATE245442T1 (de) 1995-01-19 1996-01-19 Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose

Country Status (15)

Country Link
US (2) US6649386B2 (de)
EP (4) EP1974741A1 (de)
JP (1) JP3898221B2 (de)
KR (1) KR100417593B1 (de)
CN (1) CN1152713C (de)
AT (2) ATE413885T1 (de)
AU (1) AU704317B2 (de)
CA (2) CA2210872C (de)
DE (2) DE69629209T2 (de)
DK (2) DK1308170T3 (de)
ES (2) ES2316658T3 (de)
GB (1) GB9501040D0 (de)
PT (2) PT871476E (de)
SI (1) SI1308170T1 (de)
WO (1) WO1996022107A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
DK2130554T3 (da) * 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US7799765B2 (en) * 2001-08-10 2010-09-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Association compound of trehalose or maltitol with metal ion compound
CA2538794C (en) 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
ATE489105T1 (de) * 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
DE602005016402D1 (de) 2004-05-24 2009-10-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US8133484B2 (en) 2006-12-15 2012-03-13 Lifebond Ltd Hemostatic materials and dressing
EP2114379A2 (de) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Faktor-vi- und -viia-zusammensetzungen
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
WO2009082648A1 (en) * 2007-12-21 2009-07-02 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AR069989A1 (es) 2007-12-28 2010-03-03 Baxter Int Formulaciones de vwf recombinantes
EP2334792B1 (de) 2008-09-12 2020-09-09 GenTegra LLC Matrizes und medien zur lagerung und stabilisierung von biomolekülen
NZ592704A (en) 2008-10-21 2013-02-22 Baxter Int Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
ES2706296T3 (es) 2008-11-07 2019-03-28 Univ Connecticut Formulaciones de Factor VIII
BR112012015029A2 (pt) 2009-12-22 2017-06-27 Lifebond Ltd matriz reticulada, método para controlar a formação de uma matriz, método ou matriz, método para vedar um tecido contra vazamento de um fluído corporal, agente hemostático ou vedante cirúrgico, composição para vedar um ferimento, uso da composição, composição para um veículo para entrega localizada de fármaco, composição para engenharia de tecido, e método para modificar uma composição
WO2013009254A1 (en) * 2011-07-13 2013-01-17 Denator Ab Method for stabilization of fluid biological samples
CN102416171B (zh) * 2011-12-06 2013-12-25 中国医学科学院输血研究所 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2014368594B2 (en) * 2013-12-19 2020-03-05 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
SG11201700550YA (en) 2014-08-04 2017-02-27 Csl Ltd Factor viii formulation
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles
WO2024102796A2 (en) * 2022-11-08 2024-05-16 University Of Wyoming Stabilization of biologics and human blood clotting factor viii in a dry state

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
EP0229810B1 (de) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Beschützung von proteinen und ähnlichem
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
EP1016673B1 (de) * 1992-10-02 2006-02-01 Genetics Institute, LLC Zusammensetzung, welche den Koagulationsfaktor VIII beinhalted; Verfahren zu deren Herstellung und die Benutzung eines Oberflächenaktiven Stoffes als Stabilisator
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU7254894A (en) 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater

Also Published As

Publication number Publication date
KR100417593B1 (ko) 2004-04-30
CN1152713C (zh) 2004-06-09
CA2671383A1 (en) 1996-07-25
CA2210872A1 (en) 1996-07-25
DK1308170T3 (da) 2008-12-15
US6649386B2 (en) 2003-11-18
PT1308170E (pt) 2008-12-26
SI1308170T1 (sl) 2009-04-30
GB9501040D0 (en) 1995-03-08
EP2258402A2 (de) 2010-12-08
ES2316658T3 (es) 2009-04-16
EP0871476A1 (de) 1998-10-21
EP1974741A1 (de) 2008-10-01
WO1996022107A1 (en) 1996-07-25
ES2202425T3 (es) 2004-04-01
DE69637749D1 (de) 2008-12-24
EP1308170A2 (de) 2003-05-07
EP2258402A3 (de) 2011-01-05
KR19980701500A (ko) 1998-05-15
DK0871476T3 (da) 2003-11-10
US7803911B2 (en) 2010-09-28
DE69629209T2 (de) 2004-02-19
EP1308170A3 (de) 2004-03-03
DE69629209D1 (de) 2003-08-28
JPH11503719A (ja) 1999-03-30
CN1179107A (zh) 1998-04-15
EP1308170B1 (de) 2008-11-12
JP3898221B2 (ja) 2007-03-28
PT871476E (pt) 2003-12-31
EP0871476B1 (de) 2003-07-23
US20020128207A1 (en) 2002-09-12
US20090149388A1 (en) 2009-06-11
ATE245442T1 (de) 2003-08-15
CA2671383C (en) 2012-04-24
AU704317B2 (en) 1999-04-22
AU4454096A (en) 1996-08-07
CA2210872C (en) 2009-09-08

Similar Documents

Publication Publication Date Title
ATE413885T1 (de) Getrocknete blutfaktorzusammensetzung mit trehalose
ES2136105T3 (es) Preparacion farmaceutica y/o cosmetica.
IT1276723B1 (it) Formulazioni di analoghi dell'insulina
DE3689191D1 (de) Gereinigtes protein mit angiogenischer wirkung und dessen herstellung.
FR2694804B1 (fr) Leurre stabilisée et propulsé, émettant dans l'infrarouge.
FI894097A7 (fi) Psykotrooppista vaikutusta omaavat piperatsiinidionit
DE69107566D1 (de) Flurförderfahrzeug mit Fahrerstandplatz und erhöhter Stabilität.
DK0453603T3 (da) Piroxicamholdige farmaceutiske præparater til topisk anvendelse
DE3675996D1 (de) Mittel mit kontinuierlicher peptidfreisetzung.
NO894592L (no) Pyrrolidon-2-karboksylsyre-derivater med psykotropisk virkning.
FI910112A0 (fi) Preparat foer lokalt bruk.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
DK330689D0 (da) 1,4-diazepin-derivater med anti-ulcus-virkning
ITMI932019A0 (it) Composizione farmaceutica antivirale contenente la 2-ammino 4,6-dicloropirimidina e metisoprinolo
KR940000392U (ko) 족관절 속대가 부착된 족복체
KR950026459U (ko) 착탈식 신발주머니를 가진 어린이용 책가방
DE68916472D1 (de) Polyäthylen-Zusammensetzung.
ITAN940061A0 (it) Calzatura di peso limitato e di elevate capacita' traspiranti
ES1021366Y (es) Calzado infantil
NO884783D0 (no) Anordning for regulering av lys i innendoers oppdrettsanlegg.
KR900000072U (ko) 가정용 제빵기의 공기 공급 장치
ITMI921253A1 (it) Composizione farmaceutica avente attivita' antivirale
IT8117916A0 (it) Calzatura a circolazione d'aria modulata dal piede in marcia od in sosta
ES1012015Y (es) Calzado infantil perfeccionado.
KR900016452U (ko) 성냥갑의 적린 도포장치

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1308170

Country of ref document: EP